Arsanis, Inc. (ASNS) Decreased to All-Time Low

June 29, 2018 - By Matthew Medley

Arsanis, Inc. (NASDAQ:ASNS) reached all time low on Jun, 29 with $3.48 PT or 7.00 % below the last $3.74 share price. Barchart.com published the all time low. The company has $53.46M market cap. At $3.48 PT, the company’s valuation could be $3.74M less.

ASNS is touching $3.74 during the last trading session, after decreased 6.50%.Arsanis, Inc. has 289,279 shares volume, 429.35% up from normal. ASNS is and has moved 0.00% since June 29, 2017. ASNS underperformed by 12.57% the S&P500.

Arsanis, Inc. (NASDAQ:ASNS)’s earnings report is anticipated on August, 9., as reported by Faxor. Last quarter $-0.74 earnings per share was reported. Analysts forecasts 6.76 % negative EPS growth this quarter.

For more Arsanis, Inc. (NASDAQ:ASNS) news brought out briefly go to: Benzinga.com, Businesswire.com, Benzinga.com, Benzinga.com or Benzinga.com. The titles are as follows: “Mid-Day Market Update: Crude Oil Up Over 1%; Pier 1 Imports Shares Plummet” brought out on June 28, 2018, “INVESTOR ALERT: Investigation of Arsanis Announced by Holzer & Holzer” on June 28, 2018, “50 Biggest Movers From Friday” with a publish date: June 25, 2018, “24 Stocks Moving In Friday’s Pre-Market Session” and the last “48 Biggest Movers From Yesterday” with publication date: June 29, 2018.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody immunotherapies to address serious infectious diseases.The firm is valued at $53.46 million. The Company’s lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia.Last it reported negative earnings. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis, Inc. (NASDAQ:ASNS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.